Medimmune Advancing Science for Better Health
MedImmune Advancing Science for Better Health Annual Report 2005 On the Cover SCIENCE, TECHNOLOGY AND INNOVATION ARE AT THE HEART OF MEDIMMUNE’S RESEARCH AND DEVELOPMENT EFFORTS, HELPING TO PROVIDE THE ADVANCES IN MEDICINE NEEDED FOR PATIENTS. FROM LEFT TO RIGHT, SUSAN WILSON, RESEARCH MANAGER I, WENDY WHITE, SENIOR SCIENTIST I, FRAN PALMER-HILL, RESEARCH MANAGER I, AND JOANN SUZICH, SENIOR DIRECTOR, MOLECULAR BIOLOGY AND BIOCHEMISTRY, ARE MEMBERS OF THE ORIGINAL TEAM AT MEDIMMUNE WHO PIONEERED THE DEVELOPMENT OF VIRUS-LIKE PARTICLE TECHNOLOGY IN THE MID-1990s THAT IS NOW INCORPORATED INTO HUMAN PAPILLOMAVIRUS (HPV) VACCINES IN DEVELOPMENT AT GLAXOSMITHKLINE (GSK). THIS HPV VACCINE TECHNOLOGY IS AN EXAMPLE OF OUR CONTINUING PRODUCT DEVELOPMENT PROCESSES THAT, WE BELIEVE, MAY RESULT IN SCIENTIFIC ADVANCES IN OTHER AREAS, SUCH AS INFLUENZA VACCINES AND THE TREATMENT AND PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV). Financial Highlights (in millions, except per share data) 20051,2 20042 2003 20023,4 20014 CONSOLIDATED STATEMENT OF OPERATIONS DATA Total Revenues $1,244 $1,141 $1,054 $ 853 $ 621 Gross Profit 884 758 703 589 443 Research & Development 385 327 156 148 83 Net (Loss) Earnings (17) (4) 183 (1,098) 149 Diluted (Loss) Earnings Per Share (0.07) (0.02) 0.72 (4.40) 0.68 CONSOLIDATED BALANCE SHEET DATA Cash and Investments $1,472 $1,706 $1,900 $ 1,423 $ 778 Total Assets 2,780 2,564 2,795 2,188 1,237 Long Term Debt, including current portion5 506 507 682 218 10 Total Shareholders’ Equity 1,571 1,675 1,699 1,677 1,044 1 Includes charges for acquired in-process research and development (IPR&D) in connection with the Company’s acquisition of Cellective on October 14, 2005.
[Show full text]